{"doi":"10.33540/1098","title":"Aberrant IL7R signaling: the paths towards steroid resistance in pediatric T-cell acute lymphoblastic leukemia","abstract":"Chapter 1 metabolites (methotrexate), nucleoside analogues (6-mercaptopurine, thioguanine, cytarabine) and synthetic steroids (prednisolone and dexamethasone). The ALL-11 protocol is divided into four major treatment phases over a course of at least 2 years. The first (induction) phase starts with 7 days of systemic treatment with high-dose prednisolone. The 'prednisolone response' (i.e. how many leukemic blasts are left in the peripheral blood stream after 7 days of prednisolone treatment) is an important prognostic parameter, since a 'poor prednisolone response' is associated with inferior outcome (9, 10). Other critical risk-stratification markers include minimal residue disease (MRD) at day 33 and 79 of treatment and CNS involvement. Based on these risk-stratification markers, patients are assigned to the standard, medium or high-risk treatment arm, whereas treatment in the remaining phases is most intensive in the highrisk treatment arm. Although T-ALL patients represent only 15% of ALL patients, they comprised nearly 50% of all patients treated on ALL-10 high-risk treatment regimens (11). This disproportional distribution was likely caused by the high frequency of poorprednisolone responders in the T-ALL patient group and the high proportion of patients with high MRD at day 79, which stratified patients to the high-risk arm (12, 13). In the ALL-11 protocol, a poor-prednisolone response excludes enrollment in the standard risk group and therefore still mandates for more intensive treatment with an associated risk for treatment-related morbidity and mortality.","journal":"Data Archiving and Networked Services (DANS)","year":2022,"id":306472,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9523,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1000913,"name":"Jordy Clemens Gerardus van der Zwet","orcid":null,"position":0,"is_corresponding":true}],"reference_count":451,"raw_metadata":null,"created_at":"2026-07-19T00:32:48.984902Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}